-
Options Brief: Momenta Pharmaceuticals
Thursday, June 9, 2011 - 10:00am | 82Shares of Momenta Pharmaceuticals (NASDAQ: MNTA) are higher on the session by 0.31%, trading at $19.44. Overall put volume is now running at 3.25x the daily average, with 1% of all puts traded being purchases on the offer. 2,050 contracts have traded on the session so far. Momenta...
-
Morgan Stanley Says Risks Remain On Amylin
Thursday, June 9, 2011 - 9:03am | 68According to Morgan Stanley, Amylin Pharmaceuticals (NASDAQ: AMLN) risks remain. Morgan Stanley said that it believes the latest update on the ongoing Amylin/Lilly legal battle accentuates the risks to Amylin. “While this decision is not on the breach of contract, we see most outcomes of that...
-
Elan Jumping Nearly 6% On Biogen Rumors
Thursday, June 9, 2011 - 8:40am | 93Elan Corporation, plc (NYSE: ELN) shares are soaring this morning on rumors that Biogen Idec (NASDAQ: BIIB) may bid for the company. Just the other day, Biogen said that it would be looking for deals to expand its portfolio of multiple sclerosis drugs, and Biogen has partnered with Elan on an MS...
-
Benzinga's Top Pre-Market NASDAQ Losers
Thursday, June 9, 2011 - 8:23am | 140Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) dipped 5.91% to $50 in the pre-market session. VRTX reported interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat...
-
AVI BioPharma Provides Update on Initiation of Eteplirsen Phase 2 Clinical Trial
Thursday, June 9, 2011 - 8:01am | 217AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today provided an update on the initiation of its Phase 2 clinical trial of eteplirsen, the Company's lead therapeutic candidate for the treatment of Duchenne muscular dystrophy . On June 8th, following a meeting of the...
-
Jefferies Comments on Incyte's Presentation at the 2011 Global Healthcare Conference
Thursday, June 9, 2011 - 7:40am | 92According to a recent report, Incyte (NASDAQ: INCY) presented at Jefferies 2011 Global Healthcare Conference and provided an positive update on potential ruxolitinib pricing. Additional topics discussed included the potential label on ruxolitinib, an update on the company's pricing strategy and...
-
Jefferies Maintains Buy on Dynavax Technologies
Thursday, June 9, 2011 - 7:37am | 111Jefferies is out with its report today on Dynavax Technologies (NASDAQ: DVAX), maintaining Buy. In a note to clients, Jefferies writes, "We continue to believe Heplisav may become the preferred HBV vaccine for poor responders to current vaccines and to see diabetes as a major new opportunity not...
-
A Peek Into The Market Before The Trading Starts
Thursday, June 9, 2011 - 7:32am | 392Pre-open movers US stock futures are higher this morning, as investors are awaiting trade and jobless claims data. Futures on the Dow Jones Industrial Average gained 27 points to 12,057.00 and futures on the S&P 500 stock index rose 3.60 points to 1,280.60. Nasdaq 100 futures surged 4.75 points...
-
PDL BioPharma Revises Q2 2011 Revenue Guidance to $122M
Thursday, June 9, 2011 - 7:03am | 99PDL BioPharma, Inc. (Nasdaq: PDLI) today revised its guidance for the second quarter ending June 30, 2011, to approximately $122 million, as compared with actual results of $120 million for the second quarter of 2010, an anticipated one percent year-over-year increase. The revision to the earlier...
-
Vertex Pharmaceuticals Announces Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People
Thursday, June 9, 2011 - 7:01am | 216Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic...
-
Vertex Pharmaceuticals Announces Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People
Thursday, June 9, 2011 - 7:01am | 216Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic...
-
UPDATE: Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
Wednesday, June 8, 2011 - 4:57pm | 181Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) today issued the following statement regarding the decision of the United States District Court for the Southern District of California to deny its motion for a preliminary injunction to enjoin Eli Lilly and Company (NYSE: LLY) from engaging in...
-
Immunomedics Reports Advances With New Imaging Agent Developments for Positron Emission Tomography
Wednesday, June 8, 2011 - 4:39pm | 84Immunomedics, Inc. (Nasdaq: IMMU) today announced that 4 studies, using the Company's recently patented peptide labeling method with the radioisotope fluorine-18, for improved positron emission tomography imaging of diseases, were presented at the 2011 Annual Meeting of the Society of Nuclear...
-
U.S. District Court Rules in Favor of Eli Lilly in Amylin Litigation
Wednesday, June 8, 2011 - 4:18pm | 83Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of California ruled in Lilly's favor, vacating a temporary restraining order and denying a request by Amylin Pharmaceuticals (NASDAQ: AMLN) for a preliminary injunction that sought to impose...
-
XOMA Announces Phase 2a Six-Month Top Line Trial Results Support Safety and Biological Activity
Wednesday, June 8, 2011 - 4:16pm | 141XOMA (Nasdaq: XOMA) released six-month top line results from a Phase 2a clinical trial of XOMA 052 in 74 patients with Type 2 diabetes. The results were as expected based on data from the Phase 2a three-month interim review and the Phase 2b trial. XOMA 052 was well tolerated with no significant...